What is the share price of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) today?
The share price of SHUKRAPHAR as on 6th February 2026 is ₹42.45. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Shukra Pharmaceuticals Ltd (SHUKRAPHAR) share?
The past returns of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) share are- Past 1 week: 4.10%
- Past 1 month: -17.49%
- Past 3 months: 5.68%
- Past 6 months: 117.80%
- Past 1 year: 89.42%
- Past 3 years: 2586.71%
- Past 5 years: 20114.29%
What are the peers or stocks similar to Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
The peers or stocks similar to Shukra Pharmaceuticals Ltd (SHUKRAPHAR) include:What is the dividend yield % of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) share?
The current dividend yield of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) is 0.02.What is the market cap of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) is ₹1858.80 Cr as of 6th February 2026.What is the 52 week high and low of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) share?
The 52-week high of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) is ₹65.26 and the 52-week low is ₹11.74.What is the PE and PB ratio of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) stock?
The P/E (price-to-earnings) ratio of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) is 194.03. The P/B (price-to-book) ratio is 29.58.Which sector does Shukra Pharmaceuticals Ltd (SHUKRAPHAR) belong to?
Shukra Pharmaceuticals Ltd (SHUKRAPHAR) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Shukra Pharmaceuticals Ltd (SHUKRAPHAR) shares?
You can directly buy Shukra Pharmaceuticals Ltd (SHUKRAPHAR) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Shukra Pharmaceuticals Ltd
SHUKRAPHAR Share Price
42.455.00% (+2.02)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SHUKRAPHAR Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
SHUKRAPHAR Performance & Key Metrics
SHUKRAPHAR Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 63.74 | 29.58 | 0.02% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.29 | 5.60 | 0.61% |
SHUKRAPHAR Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SHUKRAPHAR Company Profile
Shukra Pharmaceuticals is engaged in the business of manufacturing and trading of pharmaceuticals Products.
SUNPHARMA
PE Ratio
37.21
37.21
1Y Return
2.69%
2.69%
Buy Reco %
94.44
94.44
TORNTPHARM
PE Ratio
69.75
69.75
1Y Return
24.60%
24.60%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
20.38
20.38
1Y Return
9.62%
9.62%
Buy Reco %
58.06
58.06
DRREDDY
PE Ratio
18.27
18.27
1Y Return
0.37%
0.37%
Buy Reco %
51.61
51.61
LUPIN
PE Ratio
30.27
30.27
1Y Return
0.53%
0.53%
Buy Reco %
72.22
72.22
SHUKRAPHAR Forecast
SHUKRAPHAR Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
SHUKRAPHAR
SHUKRAPHAR
Income
Balance Sheet
Cash Flow
Annual Normal View
SHUKRAPHAR Income Statement
SHUKRAPHAR Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5.21 | 5.48 | 5.70 | 11.95 | 11.56 | 20.57 | 60.03 | 77.39 | 36.80 | 68.78 | ||||||||||
Raw Materials | 0.95 | 0.89 | 1.16 | 3.33 | 2.96 | 11.08 | 45.65 | 43.78 | 11.75 | 28.32 | ||||||||||
| Power & Fuel Cost | 0.26 | 0.29 | 0.34 | 1.64 | 1.78 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||
| Employee Cost | 1.05 | 1.23 | 1.91 | 4.34 | 3.75 | 4.57 | 4.41 | 5.02 | 5.47 | |||||||||||
| Selling & Administrative Expenses | 0.92 | 1.20 | 0.71 | 1.21 | 1.36 | 2.44 | 3.38 | 5.15 | 5.83 | |||||||||||
| Operating & Other expenses | 0.49 | 0.15 | -0.11 | -0.21 | 0.10 | -0.49 | 0.03 | 1.21 | -3.18 | |||||||||||
EBITDA | 1.54 | 1.72 | 1.69 | 1.64 | 1.61 | 2.97 | 6.56 | 22.23 | 16.93 | 40.46 | ||||||||||
| Depreciation/Amortization | 0.47 | 0.74 | 0.96 | 1.48 | 1.47 | 1.66 | 1.84 | 2.05 | 3.00 | 3.38 | ||||||||||
| PBIT | 1.07 | 0.98 | 0.73 | 0.16 | 0.14 | 1.31 | 4.72 | 20.18 | 13.93 | 37.08 | ||||||||||
| Interest & Other Items | 0.01 | 0.04 | 0.00 | 0.00 | 0.03 | 0.29 | 0.28 | 0.29 | 0.59 | 1.11 | ||||||||||
| PBT | 1.06 | 0.94 | 0.73 | 0.16 | 0.11 | 1.02 | 4.44 | 19.89 | 13.34 | 35.97 | ||||||||||
| Taxes & Other Items | 0.55 | 0.42 | 0.27 | 0.14 | -0.09 | 0.27 | 0.04 | 1.34 | 3.76 | 6.81 | ||||||||||
| Net Income | 0.51 | 0.52 | 0.46 | 0.02 | 0.20 | 0.75 | 4.40 | 18.55 | 9.58 | 29.16 | ||||||||||
| EPS | 0.02 | 0.02 | 0.02 | 0.00 | 0.01 | 0.02 | 0.24 | 0.74 | 0.22 | 0.67 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | 0.01 | 0.01 | ||||||||||
| Payout ratio | 0.15 | 0.15 | 0.17 | 0.00 | 0.00 | 0.10 | 0.05 | 0.03 | 0.05 | 0.02 |
SHUKRAPHAR Company Updates
SHUKRAPHAR Stock Peers
SHUKRAPHAR Past Performance & Peer Comparison
SHUKRAPHAR Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Shukra Pharmaceuticals Ltd | 194.03 | 29.58 | 0.02% |
| Sun Pharmaceutical Industries Ltd | 37.21 | 5.61 | 0.94% |
| Torrent Pharmaceuticals Ltd | 69.75 | 17.56 | 0.81% |
| Cipla Ltd | 20.38 | 3.43 | 1.20% |
SHUKRAPHAR Stock Price Comparison
Compare SHUKRAPHAR with any stock or ETFCompare SHUKRAPHAR with any stock or ETF
SHUKRAPHAR
SHUKRAPHAR Holdings
SHUKRAPHAR Shareholdings
SHUKRAPHAR Promoter Holdings Trend
SHUKRAPHAR Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SHUKRAPHAR Institutional Holdings Trend
SHUKRAPHAR Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SHUKRAPHAR Shareholding Pattern
SHUKRAPHAR Shareholding Pattern
SHUKRAPHAR Shareholding History
SHUKRAPHAR Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing SHUKRAPHAR stock
smallcases containing SHUKRAPHAR stock
Looks like this stock is not in any smallcase yet.
SHUKRAPHAR Events
SHUKRAPHAR Events
SHUKRAPHAR Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SHUKRAPHAR Dividend Trend
No dividend trend available
SHUKRAPHAR Upcoming Dividends
SHUKRAPHAR Upcoming Dividends
No upcoming dividends are available
SHUKRAPHAR Past Dividends
SHUKRAPHAR Past Dividends
Cash Dividend
Ex DateEx DateSep 18, 2025
Final
Final | Div/Share: ₹0.01
Dividend/Share
₹0.01
Ex DateEx Date
Sep 18, 2025
Cash Dividend
Ex DateEx DateSep 23, 2024
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 23, 2024
Cash Dividend
Ex DateEx DateSep 15, 2023
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 15, 2023
Cash Dividend
Ex DateEx DateSep 22, 2022
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 22, 2022
Cash Dividend
Ex DateEx DateSep 19, 2019
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 19, 2019
SHUKRAPHAR Stock News & Opinions
SHUKRAPHAR Stock News & Opinions
Articles & Videos
Earnings
Shukra Pharmaceuticals standalone net profit rises 544.30% in the December 2025 quarter
Net profit of Shukra Pharmaceuticals rose 544.30% to Rs 20.36 crore in the quarter ended December 2025 as against Rs 3.16 crore during the previous quarter ended December 2024. Sales rose 269.85% to Rs 39.13 crore in the quarter ended December 2025 as against Rs 10.58 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales39.1310.58 270 OPM %69.3137.15 - PBDT27.664.79 477 PBT26.824.09 556 NP20.363.16 544 Powered by Capital Market - Live
4 days agoCapital Market - Live
Corporate
Shukra Pharmaceuticals revises board meeting date
Shukra Pharmaceuticals has revised the meeting of the Board of Directors which was scheduled to be held on 7 February 2026. The meeting will now be held on 4 February 2026.Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Shukra Pharmaceuticals to hold board meeting
Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 4 February 2026.Powered by Capital Market - Live
1 week agoCapital Market - Live
Spotlight
Shukra Pharma inks MoU with US-based Borns Medical Robotics for surgical robotic systems
The MOU sets out the framework for collaboration between the parties to introduce, promote and commercialize next-generation Al-enabled soft-tissue surgical robotic systems across lndia and select South Asian markets, including Nepal, Bangladesh, Sri Lanka, Maldives and Bhutan, subject to applicable regulatory approvals. Shukra Pharmaceuticals stated that this collaboration will focus on expanding access to robot-assisted minimally invasive surgeries, integrating AI-driven digital surgery workflows to improve standardization and efficiency, and strengthening regional healthcare infrastructure through technology transfer and clinician training. Borns Medical Robotics will contribute its surgical robotics and AI expertise, while the company will leverage its regulatory capabilities and healthcare market reach across India and South Asia. The collaboration supports the company's long-term strategy of expanding into high-value, technology-led healthcare segments. It is expected to strengthen its medical technology portfolio and market positioning, unlock new revenue opportunities through commercialization and hospital partnerships, enhance brand visibility and competitiveness in digital healthcare, and contribute to sustainable long-term shareholder value by gaining exposure to the fast-growing global surgical robotics market. The MOU is non-binding in nature and outlines the intent of the parties to explore definitive agreements in due course, subject to detailed commercial terms, regulatory approvals, and mutual consent,' the company said in a statement. Shukra Pharmaceuticals manufactures and markets pharmaceutical products and does laboratory testing. The company's consolidated net profit surged to Rs 2.38 crore in the quarter ended September 2025 as against Rs 0.54 crore during the previous quarter ended September 2024. Sales rose 5.76% to Rs 5.88 crore in Q2 FY26 over Q2 FY25. The scrip had declined 4.98% to end at Rs 54.15 on the BSE today. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Shukra Pharmaceuticals standalone net profit rises 340.74% in the September 2025 quarter
Net profit of Shukra Pharmaceuticals rose 340.74% to Rs 2.38 crore in the quarter ended September 2025 as against Rs 0.54 crore during the previous quarter ended September 2024. Sales rose 5.76% to Rs 5.88 crore in the quarter ended September 2025 as against Rs 5.56 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales5.885.56 6 OPM %-6.9712.05 - PBDT1.011.58 -36 PBT0.200.88 -77 NP2.380.54 341 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Shukra Pharmaceuticals to declare Quarterly Results
Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Shukra Pharmaceuticals schedules EGM
Shukra Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 1 November 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Shukra Pharmaceuticals to discuss results
Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 3 October 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Shukra Pharmaceuticals to hold AGM
Shukra Pharmaceuticals announced that the Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Shukra Pharmaceuticals schedules AGM
Shukra Pharmaceuticals announced that the 32th Annual General Meeting(AGM) of the company will be held on 29 September 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 25.23%, vs industry avg of 10.04%
Over the last 5 years, market share increased from 0% to 0.01%
Over the last 5 years, net income has grown at a yearly rate of 243.61%, vs industry avg of 20.02%